Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE Registry
Clinical Gastroenterology and Hepatology · 2025
DOI: 10.1016/j.cgh.2024.05.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025. Verfasst von Steven H Itzkowitz und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: steven.itzkowi…. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Neoplasms, Immunosuppressive Agents, Immunosuppression Therapy. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCI NIH HHS, Crohn's and Colitis Foundation of America.
Abstract (Originalsprache)
BACKGROUND & AIMS: In patients with inflammatory bowel disease (IBD) and a history of cancer, retrospective studies have suggested that exposure to immunosuppressive agents does not increase the risk of incident (recurrent or new) cancer compared with unexposed patients. Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients and a HIstoRy of CancEr (SAPPHIRE) is a prospective registry aimed at addressing this issue. METHODS: Since 2016, patients with IBD and confirmed index cancer before enrollment were followed up annually. Patients receiving chemotherapy or radiation at enrollment, or recurrent cancer within 5 years, were excluded. The primary outcome was development of incident cancer related to exposure to immunosuppressive medications. RESULTS: Among 305 patients (47% male, 88% white), the median age at IBD diagnosis and cancer were 32 and 52 years, respectively. Index cancers were solid organ (46%), dermatologic (32%), gastrointestinal (13%), and hematologic (9%). During a median follow-up period of 4.8 years, 210 patients (69%) were exposed to immunosuppressive therapy and 46 patients (15%) developed incident cancers (25 new, 21 recurrent). In unadjusted analysis, the crude rate of incident cancer in unexposed patients was 2.58 per 100 person-years vs 4.78 per 100 person-years (relative risk, 1.85; 95% CI, 0.92-3.73) for immunosuppression-exposed patients. In a time-varying proportional hazards model adjusting for sex, smoking history, age and stage at index malignancy, and nonmelanoma skin cancer, no significant association was found between receipt of immunosuppression and incident cancer (adjusted hazard ratio, 1.41; 95% CI, 0.69-2.90), or with any major drug class. CONCLUSIONS: In this interim analysis of patients with IBD and a history of cancer, despite numerically increased adjusted hazard ratios, we did not find a statistically significant association between subsequent exposure to immunosuppressive therapies and development of incident cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: steven.itzkowitz@mountsinai.org.
- Department of Statistical Science, Duke University, Durham, North Carolina.
- Department of Population Health, Icahn School of Medicine at Mount Sinai, New York, New York.
- Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
- Division of Gastroenterology, Department of Medicine, Northwell Health-North Shore University Hospital, Zucker School of Medicine, Manhasset, New York.
- Division of Gastroenterology, Department of Medicine, Weill Cornell Medicine, New York, New York.
Förderung
- NIDDK NIH HHS
- NCI NIH HHS
- Crohn's and Colitis Foundation of America
- Leona M and Harry B Helmsley Charitable Trust
Zitieren
APA
Itzkowitz, S. H., Jiang, Y., Villagra, C., Colombel, J. F., Sultan, K., Lukin, D. J., Faleck, D. M., Scherl, E., Chang, S., Chen, L., Katz, S., Kwah, J., Swaminath, A., Petralia, F., Sharpless, V., Sachar, D., Jandorf, L., Axelrad, J. E., & New York Crohn’s and Colitis Organization (2025). Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE Registry. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.05.006
Vancouver
Itzkowitz SH, Jiang Y, Villagra C, Colombel JF, Sultan K, Lukin DJ, et al. Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE Registry. Clinical Gastroenterology and Hepatology. 2025. doi:10.1016/j.cgh.2024.05.006
BibTeX
@article{Itzkowitz2025,
author = {Itzkowitz, Steven H and Jiang, Yue and Villagra, Cristina and Colombel, Jean-Frederic and Sultan, Keith and Lukin, Dana J and Faleck, David M and Scherl, Ellen and Chang, Shannon and Chen, LeaAnn and Katz, Seymour and Kwah, Joann and Swaminath, Arun and Petralia, Francesca and Sharpless, Virginia and Sachar, David and Jandorf, Lina and Axelrad, Jordan E and New York Crohn’s and Colitis Organization, New York Crohn’s and Colitis Organization},
title = {Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE Registry},
journal = {Clinical Gastroenterology and Hepatology},
year = {2025},
doi = {10.1016/j.cgh.2024.05.006}
}
EUVIMED